London, UK 4/3/17—Life science measurement and testing firm LGC has purchased Germany-based Axolabs, a contract research, development and manufacturing organization that specializes in Therapeutic Nucleic Acid (TNA) development. Axolab has 60 employees. “Axolabs’ in-depth know-how in the TNA drug development field complements LGC’s capabilities in GMP oligo manufacture, CMC [Chemistry, Manufacturing, and Control] analytical and bioanalytical services, and we look forward to working together with the Axolabs team and its customers,” said Dr. David Griffiths, managing director of LGC’s Laboratory & Managed Services division.

The acquisition further expands LGC’s oligo-related offerings for therapeutic applications, which include its 2016 purchase of Prime Synthesis (see IBO 11/30/16). Axolabs’ capabilities include in-silico design, synthesis, analytics, bioanalytics, biology, pharmacology and consulting services.